MeiraGTx Holdings ^{Priced, Nasdaq: MGTX}

We are a vertically integrated, clinical stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and research programs. We have core capabilities in viral vector design and optimization, gene therapy manufacturing as well as a potentially transformative gene regulation technology. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland and central nervous system, we intend to expand to a range of serious diseases. Eye diseases are our first area of clinical focus. We currently have three ongoing clinical programs for eye diseases in inherited retinal diseases (IRDs) with an additional program expected to initiate a Phase 1/2 clinical trial in 2019. We are also targeting xerostomia, a chronic and debilitating disorder of the salivary glands in which saliva production is impaired. A Phase 1 clinical trial of our gene therapy product candidate is ongoing in patients who have survived cancer free for five or more years following treatment for head and neck cancer and are suffering from grade 2 or 3 radiation induced late xerostomia, or RIX. We were formed in 2015 through the acquisition of Athena Vision Ltd. from University College of London and certain assets from Kadmon Corporation (Nasdaq: KDMN).